COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC 50 of 445 nM.
性状
Solid
IC50 & Target[1][2]
IC50: 445 nM (nAChR)
体内研究(In Vivo)
COG 133 (1 mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisturePowder -80°C 2 years;-20°C 1 year